Patent: 9,636,344
✉ Email this page to a colleague
Summary for Patent: 9,636,344
Title: | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts |
Abstract: | The present invention relates to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-- c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): ##STR00001## or a tautomer, solvate or hydrate thereof; and to its use for the treatment of non-Hodgkin\'s lymphoma. |
Inventor(s): | Peters; Jan-Georg (Solingen, DE), Militzer; Hans-Christian (Odenthal, DE), Muller; Hartwig (Velbert, DE) |
Assignee: | Bayer Intellectual Property GmbH (Monheim, DE) |
Application Number: | 14/990,350 |
Patent Claims: | see list of patent claims |
Details for Patent 9,636,344
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2031-04-05 |
Amgen, Inc. | EPOGEN/PROCRIT | epoetin alfa | Injection | 103234 | 06/01/1989 | ⤷ Try a Trial | 2031-04-05 |
Amgen, Inc. | EPOGEN/PROCRIT | epoetin alfa | Injection | 103234 | ⤷ Try a Trial | 2031-04-05 | |
Amgen, Inc. | PROCRIT | epoetin alfa | Injection | 103234 | ⤷ Try a Trial | 2031-04-05 | |
Clinigen, Inc. | PROLEUKIN | aldesleukin | For Injection | 103293 | 05/05/1992 | ⤷ Try a Trial | 2031-04-05 |
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 02/20/1991 | ⤷ Try a Trial | 2031-04-05 |
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 06/28/2000 | ⤷ Try a Trial | 2031-04-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |